Single dose of rexlemestrocel-l provides substantial and durable reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure

New york, jan. 11, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results from the landmark dream-hf randomized controlled phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (hfref) who received rexlemestrocel-l (revascor®) or control sham. a single dose of rexlemestrocel-l resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths. since existing therapies have only minimal or no benefit on these endpoints, these notable outcomes may signal a breakthrough in addressing the principal unmet needs in patients with chronic heart failure. the results of this trial identify new york heart association (nyha) class ii hfref patients as the optimal target population for greatest rexlemestrocel-l treatment effect, and therefore a focus for registration and commercialization of rexlemestrocel-l in the largest market in heart failure.
MESO Ratings Summary
MESO Quant Ranking